论文部分内容阅读
目的:观察真武汤联合坦索罗辛治疗良性前列腺增生症的临床疗效。方法:将80例患者随机分为2组各40例,对照组采用坦索罗辛治疗,试验组在对照组的基础上联合真武汤治疗,观察比较2组临床疗效、相关疗效指标改善情况及不良反应。结果:总有效率试验组为97.5%,对照组为55.0%,2组比较,差异有统计学意义(P<0.05)。治疗后试验组最大尿流量(MFR)大于对照组,前列腺体积(PV)、残余尿量(PVR)小于对照组,差异均有统计学意义(P<0.05)。总不良反应率试验组为5.0%,对照组为37.5%,2组比较,差异有统计学意义(P<0.05)。结论:坦索罗辛与真武汤联合治疗良性前列腺增生症效果显著,不良反应较少,安全可靠。
Objective: To observe the clinical efficacy of Zhenwu Decoction combined with tamsulosin in the treatment of benign prostatic hyperplasia. Methods: Eighty patients were randomly divided into two groups of 40 cases. The control group was treated with tamsulosin. The experimental group was treated with Zhenwu Decoction on the basis of the control group. The clinical curative effect and the improvement of related curative indexes were observed and compared Adverse reactions. Results: The total effective rate was 97.5% in the experimental group and 55.0% in the control group. There was significant difference between the two groups (P <0.05). After treatment, the maximal urinary flow (MFR) in the experimental group was greater than that in the control group, and the volume of prostate and PVR was lower than that of the control group (P <0.05). The total adverse reaction rate was 5.0% in the test group and 37.5% in the control group. There was significant difference between the two groups (P <0.05). Conclusion: Tamsulosin and Zhenwu Decoction combined treatment of benign prostatic hyperplasia have significant effect, less adverse reactions, safe and reliable.